Challenges in Bringing Generic Drug Manufacturing Back to America

This article discusses the difficulties faced by the United States in increasing domestic production of generic drugs, highlighting lessons from India. It points out that factors such as cheap labor and established global supply chains complicate efforts to reshore manufacturing. The analysis comes in the context of President Trump's plan to boost American generic drug production.

Originally published by nyt